Managing CLL with Del 11q and unmutated status alongside a heart medication is understandably a lot to navigate. These are very valid concerns to bring up with your care team, as they need to know all medications being taken when planning CLL treatment.
For aggressively progressing CLL with Del 11q, doctors often consider Show Full Answer
Managing CLL with Del 11q and unmutated status alongside a heart medication is understandably a lot to navigate. These are very valid concerns to bring up with your care team, as they need to know all medications being taken when planning CLL treatment.
For aggressively progressing CLL with Del 11q, doctors often consider targeted therapies. Some commonly used options include:
- BTK inhibitors like ibrutinib (Imbruvica) or acalabrutinib (Calquence)
- BCL-2 inhibitors like venetoclax (Venclexta), sometimes combined with other drugs
- Monoclonal antibodies like obinutuzumab (Gazyva) or rituximab (Rituxan)
It's worth noting that ibrutinib in particular has known heart-related considerations, so your doctor will want to factor in your heart medication carefully when choosing the right treatment path. A MyLeukemiaTeam member once shared that their hematologist regularly asks about all aspects of their health, including stress and other medications. Being open and transparent with your oncologist and cardiologist — ideally having them communicate with each other — is really the best step here.
Don't hesitate to ask your doctor specifically: *"How does my heart medication interact with my CLL treatment options?"* That conversation could shape which treatment is safest and most effective for your specific situation.
August 19
Join
Your Privacy Choices
